TheraCIM

TheraCIM Dosage/Direction for Use

nimotuzumab

Manufacturer:

Innogene Kalbiotech

Distributor:

Alliance Pharma
Full Prescribing Info
Dosage/Direction for Use
Relapsed High-Grade Glioma: Children and Adolescents: Monotherapy in 2 consecutive phases. Induction Phase: 150 mg/m2 body surface area (BSA) weekly for 6 weeks. Consolidation Phase: After induction phase, patients without progressive disease upon 8th week evaluation will be given with 150 mg/m2 BSA every 3 weeks until disease progression.
Relapsed High-Grade Glioma In Combination with Radiation Therapy: Adults: 200 mg weekly for 6 weeks with radiation and maintenance with 200 mg every 21 days for 1 year.
SCCHN: 200 mg once weekly for 6-8 weeks in combination with standard radiotherapy or chemoradiotherapy by continuous IV infusion.
Administration: TheraCIM is administered as continuous IV infusions as monotherapy for relapsed glioma in pediatric/adolescent. Nimotuzumab is diluted in 250 mL of sodium chloride 0.9% solution and administered IV within 30 min. Pre-treatment with diphenhydramine is recommended to minimize possible infusion reaction.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in